JOURNAL OF CLINICAL SURGERY ›› 2024, Vol. 32 ›› Issue (1): 92-95.doi: 10.3969/j.issn.1005-6483.2024.01.025

Previous Articles     Next Articles

Advancements in the treatment of malignancies using a combination of immune checkpoint inhibitors and immunomodulators

  

  1. Hepatic Surgery Center,Tongji Hospital,Tongji Medical College Huazhong University of Science and Technology,Wuhan 430030,China
  • Received:2023-11-07 Accepted:2023-11-07 Online:2024-01-20 Published:2024-01-20

Abstract: In recent years,there have been significant advancements in tumor immunotherapy.Immune checkpoint inhibitors have emerged as a pivotal approach for treating advanced malignant tumors.The use of immunotherapy has been widely recommended and applied in clinical treatment both domestically and internationally.However,its clinical treatment efficacy still falls short of expectations.Improving the efficacy of immunotherapy for patients with advanced malignant tumors is currently a prominent research focus.Studies indicate that the combined use of immune enhancers and immune checkpoint inhibitors in various advanced malignant tumors significantly enhances the outcomes of immunotherapy.This article primarily highlights the combined application of immune enhancers and immune checkpoint inhibitors in cancer therapy,offering insights into their potential in the field of oncology treatment.

Key words: malignant tumors, immunotherapy, immune checkpoint inhibitors, immunomodulators, combination therapy

[1] LI Dawei, XIA Shihui. Influencing factors of disease-free survival in patients with stage Ⅲ non-small cell lung cancer after neoadjuvant chemotherapy combined with immunotherapy [J]. JOURNAL OF CLINICAL SURGERY, 2023, 31(7): 626-629.
[2] LONG Xinglin, XIE Songping, LIU Gaoli, ZHang Wenhan, HUANG Jie. Clinical efficacy of immunotherapy combined with chemotherapy sequential surgery for locally advanced esophageal cancer [J]. JOURNAL OF CLINICAL SURGERY, 2023, 31(11): 1040-1043.
[3] GUO Xinyi, Yu Yahong. [J]. JOURNAL OF CLINICAL SURGERY, 2023, 31(11): 1107-1110.
[4] DU Jiajia, HUANG Zhiyong. Predictive biomarkers of immunotherapy response in patients with hepatocellular carcinoma [J]. JOURNAL OF CLINICAL SURGERY, 2023, 31(10): 990-993.
[5] TIAN Wenze, XIONG Xinkui, XU Dafu, et al. The study of conversion therapy with carrelizumab combined with chemotherapy in unresectable locally advanced esophageal cancer [J]. JOURNAL OF CLINICAL SURGERY, 2022, 30(8): 741-743.
[6] YUAN Tong, HUANG Zhiyong. Hepatocellular carcinoma immunotherapy 4.0 [J]. JOURNAL OF CLINICAL SURGERY, 2022, 30(5): 490-493.
[7] ZHU Xingwu, QIU Maixuan, LI Jing. Progress of immunotherapy in advanced biliary tract cancer [J]. JOURNAL OF CLINICAL SURGERY, 2022, 30(11): 1098-1100.
[8] . Clinical application of autologous tumor infiltrating lymphocytes combined with antiPD1 antibody in the treatment of advanced hepatocellular carcinoma [J]. JOURNAL OF CLINICAL SURGERY, 2021, 29(8): 743-747.
[9] . Research progress in neoadjuvant treatment of esophageal squamous cell carcinoma [J]. JOURNAL OF CLINICAL SURGERY, 2021, 29(8): 784-787.
[10] LI Jiang, HUANG Zhiyong.. Advances in immune microenvironment and immunotherapy of hepatocellular carcinoma [J]. JOURNAL OF CLINICAL SURGERY, 2021, 29(11): 1089-1091.
[11] DENG Yu, HAO Bo, GENG Qing.. Current status and prospect of treatment for small cell lung cancer [J]. JOURNAL OF CLINICAL SURGERY, 2020, 28(7): 696-699.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!